Last €18.35 EUR
Change Today +0.15 / 0.82%
Volume 110.2K
NANO On Other Exchanges
Symbol
Exchange
EN Paris
As of 11:35 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

nanobiotix (NANO) Snapshot

Open
€18.20
Previous Close
€18.20
Day High
€18.77
Day Low
€18.18
52 Week High
02/13/14 - €30.28
52 Week Low
12/20/13 - €4.57
Market Cap
239.8M
Average Volume 10 Days
304.3K
EPS TTM
--
Shares Outstanding
13.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOBIOTIX (NANO)

Related News

No related news articles were found.

nanobiotix (NANO) Related Businessweek News

No Related Businessweek News Found

nanobiotix (NANO) Details

Nanobiotix S.A., a clinical-stage nanomedicine company, engages in the development of tools for the treatment of cancer. Its product pipeline includes NanoXray products comprising NBTXR3 nanoparticles that are designed for direct injection into the tumor; NBTX-IV nanoparticles designed for intravenous injection to reach the tumor and the surrounding tissue; and NBTX-TOPO nanoparticles, a gel applied during surgery after removal of the tumor in various types of breast cancer, brain tumors, and retroperitoneal soft tissue sarcomas. The company also develops nanoMag magnetic particles for treatment and diagnostic of cancer; and nanoPDT laser activated nanoparticles for the treatment of cancer. It has a licensing contract with PharmaEngine, Inc. for the development of NBTXR3; and business and development collaboration with Malaysian Biotech Corp. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

40 Employees
Last Reported Date: 05/1/14
Founded in 2003

nanobiotix (NANO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nanobiotix (NANO) Key Developments

NANOBIOTIX Receives First Approval to Start Phase II/III Registration Trial in Soft Tissue Sarcoma in Europe

NANOBIOTIX announced that it has received approval from the French National Security Agency for Medicines and Health Products to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS). Patients with locally advanced STS have very limited therapeutic options. A standard treatment of care before surgery is radiotherapy aiming to reduce the tumor volume. Thereafter surgery is still required to remove the tumor. But despite of radiotherapy, a considerable proportion of patients with advanced tumors that cannot be resected in their entirety. The remaining tumor mass promotes the further development of the disease resulting in a poor prognosis for the patient. NBTXR3 has the potential to provide a significant clinical benefit by improving radiotherapy efficacy, destroying locally advanced tumors more efficiently and to improve the quality of surgery enabling a more complete removal of the tumor. This international multi-center pivotal study will start in France and then be conducted in around 25-30 sites throughout Europe once further authorizations are received. This pivotal trial is expected to be the final step before registration in Europe (CE mark) and should be completed towards the end of 2016.

Nanoco Inks Joint Development Agreement with Osram

Nanoco Group plc announced that it has signed a follow-on joint development agreement with Osram. Quantum dots open up new potential for LED lighting -- which currently lacks the same warmth and color performance of an incandescent bulb -- and have the capacity to appeal to a new set of buyers who want the efficiency and economy of the LED, as well as the effect of natural light.

PharmaEngine Inc. and Nanobiotix SA Strengthen Collaboration for a Global Pivotal Trial of NBTXR3 in Soft Tissue Sarcoma

PharmaEngine Inc. and Nanobiotix SA announced that the companies had strengthened their collaboration by jointly conducting a global pivotal trial of NBTXR3 in soft tissue sarcoma (STS) in Europe and Asia. Nanobiotix expects recruitment of the first patient in Europe by the end of 2014. In conjunction with the accelerated clinical development, PharmaEngine will make a milestone payment of $1 million to Nanobiotix. In August 2012, PharmaEngine licensed the development and commercialization rights of NBTXR3 (designated as PEP503 by PharmaEngine) in Asia-Pacific region from Nanobiotix. Nanobiotix reported results of a pilot study of STS in mid-2014. Twenty patients were enrolled and received a single intratumoral injection of NBTXR3 (PEP503), at escalating volumes, followed by five weekly sessions of standard radiotherapy (50 Gy), after which the patients underwent surgical resection. The treatment regimen was well tolerated and showed promising signs of anti-tumor activity. The positive results of the study were presented by Nanobiotix at the American Society of Clinical Oncology Annual Meeting in June 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NANO:FP €18.35 EUR +0.15

NANO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NANO.
View Industry Companies
 

Industry Analysis

NANO

Industry Average

Valuation NANO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 105.2x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 103.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOBIOTIX, please visit www.nanobiotix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.